Bespak granted new drug delivery patent
UK drug delivery systems company Bespak has been granted a new patent for enhancements in the design and manufacture of its drug delivery actuators.
UK drug delivery systems company Bespak has been granted a new patent for enhancements in the design and manufacture of its drug delivery actuators.
The development is said to deliver improved reliability in the manufacturing process, providing increased assurance that a precise dose of a drug formula is administered to a patient.
It achieves a reduction in product variability by ensuring that the polymer is of even thickness. This means that upon leaving the mould tool the stem material cools evenly, reducing the likelihood of distortion. Importantly, this ensures the spray plume emitted from the complete device is delivered into the user's mouth instead of being impacted in the inner mouthpiece.
To support its work in the development of actuators and pressurised metered dose inhalers, Bespak has invested in a multi-million pound building programme at its site in King's Lynn, UK. Scheduled for completion during 2003, the new manufacturing facility will extend the company's production capabilities and drive the business forward as a front runner in the development of delivery systems for inhaled therapies.